Mutagenic Assessment of Olmesartan Cilexetil by Bacterial Mutation Assay

Hypertension is a serious health problem due to high frequency and concomitant other diseases including cardiovascular and renal dysfunction. Olmesartan cilexetil is a new antihypertensive drug associated with angiotensin II receptor antagonist. This study was conducted to evaluate the mutagenicity...

Full description

Saved in:
Bibliographic Details
Published inToxicological research (Seoul) Vol. 29; no. 3; pp. 217 - 219
Main Authors Kim, Ji Won, Ahn, Ilyoung, Ryu, Sung Ha, Jeon, Hong Ryeol, Lee, Bong Sang, Kim, Kyu-Bong
Format Journal Article
LanguageKorean
Published 2013
Subjects
Hypertension
Olmesartan cilexetil
Mutagenicity
Angiotension II receptor antagonist
Online AccessGet full text

Cover

More Information
Summary:Hypertension is a serious health problem due to high frequency and concomitant other diseases including cardiovascular and renal dysfunction. Olmesartan cilexetil is a new antihypertensive drug associated with angiotensin II receptor antagonist. This study was conducted to evaluate the mutagenicity of olmesartan cilexetil by bacterial reverse mutation test using Salmonella typhimurium (TA100, TA1535, TA98, and TA1537) and Escherichia coli (WP2 uvrA). At the concentrations of 0, 62, 185, 556, 1667, and 5000 ${\mu}g$/plate, olmesartan cilexetil was negative in both Salmonella typhimurium and Escherichia coli regardless of presence or absence of metabolic activation system (S9 mix). These results demonstrate that olmesartan cilexetil does not induce bacterial reverse mutation.
Bibliography:KISTI1.1003/JNL.JAKO201332479079205
ISSN:1976-8257
2234-2753